2. Search Result
Search Result
Results for "

MKP-1

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108543
    NSC 95397
    5+ Cited Publications

    		 Phosphatase Apoptosis Cancer
    NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (Ki=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC50=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)) [1]. NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway .
    NSC 95397
  • HY-13866
    Ro 31-8220 mesylate
    Maximum Cited Publications
    13 Publications Verification

    Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate

    		 PKC JNK Cardiovascular Disease Neurological Disease Cancer
    Ro 31-8220 mesylate is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 mesylate can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC [1] .
    Ro 31-8220 mesylate
  • HY-P10408
    Candidalysin

    		EGFR MMP Calcium Channel NOD-like Receptor (NLR) ERK p38 MAPK Infection Inflammation/Immunology
    Candidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates LDH causing membrane damage and exhibiting cytotoxicity [1]
    Candidalysin
  • HY-B2162D
    Chondroitin sulfate (from chicken)

    Chondroitin polysulfate (from chicken)

    		 ERK p38 MAPK Interleukin Related TNF Receptor Prostaglandin Receptor MMP Endogenous Metabolite Inflammation/Immunology
    Chondroitin sulfate (from chicken) (Chondroitin polysulfate (from chicken)) is an orally active, sulfated linear polysaccharide extracted from chickens, which belongs to glycosaminoglycans. Chondroitin sulfate (from chicken) reduces the phosphorylation levels of ERK1/2 and p38MAPK, inhibits the expression of inflammatory cytokines and MMP, and downregulates the levels of IL-1β, IL-6, TNF-α and PGE2. Chondroitin sulfate (from chicken) improves motor function, protects cartilage tissue, reverses chondrocyte aggregation, and regulates the structure of intestinal flora. Chondroitin sulfate (from chicken) can be used in research related to osteoarthritis [1].
    Chondroitin sulfate (from chicken)
  • HY-13866B
    Ro 31-8220 formic
    Maximum Cited Publications
    13 Publications Verification

    Bisindolylmaleimide IX formic

    		 PKC JNK Cancer
    Ro 31-8220 formic is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 formic also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively). Ro 31-8220 formic can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC [1] .
    Ro 31-8220 formic
  • HY-13866A
    Ro 31-8220

    Bisindolylmaleimide IX

    		 PKC JNK Cardiovascular Disease Neurological Disease
    Ro 31-8220 is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC [1] .
    Ro 31-8220
  • HY-178297
    VHR-IN-7

    		Phosphatase Cancer
    VHR-IN-7 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 71 nM. VHR-IN-7 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.47 μM), CD45 (IC50 = 0.3 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 0.59 μM), and HePTP (IC50 = 1.2 μM). VHR-IN-7 inhibits the proliferation of HeLa cells. VHR-IN-7 can be used for the research of cervical cancer [1].
    VHR-IN-7
  • HY-178296
    VHR-IN-6

    		Phosphatase Cancer
    VHR-IN-6 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 74 nM. VHR-IN-6 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.52 μM), CD45 (IC50 = 0.50 μM), Cdc25A (IC50 = 2.8 μM), PTP1B (IC50 = 0.42 μM), and HePTP (IC50 = 0.87 μM). VHR-IN-6 inhibits the proliferation of HeLa cells. VHR-IN-6 can be used for the research of cervical cancer [1].
    VHR-IN-6
  • HY-178301
    VHR-IN-9

    		Phosphatase Cancer
    VHR-IN-9 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 270 nM. VHR-IN-9 shows very weaker inhibitory activity against MKP-1 (IC50 = 2.8 μM), CD45 (IC50 = 1.8 μM), Cdc25A (IC50 = > 10 μM), PTP1B (IC50 = 2.2 μM), and HePTP (IC50 = 2.4 μM). VHR-IN-9 inhibits the proliferation of HeLa cells. VHR-IN-9 can be used for the research of cervical cancer [1].
    VHR-IN-9
  • HY-178295
    VHR-IN-5

    		Phosphatase Cancer
    VHR-IN-5 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 78 nM. VHR-IN-5 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.78 μM), CD45 (IC50 = 0.61 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 1.8 μM), and HePTP (IC50 = 1.5 μM). VHR-IN-5 inhibits the proliferation of HeLa cells. VHR-IN-5 can be used for the research of cervical cancer [1].
    VHR-IN-5
  • HY-RS16828
    Dusp1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Dusp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dusp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dusp1 Mouse Pre-designed siRNA Set A
    Dusp1 Mouse Pre-designed siRNA Set A
  • HY-RS04050
    DUSP1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DUSP1 Human Pre-designed siRNA Set A contains three designed siRNAs for DUSP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DUSP1 Human Pre-designed siRNA Set A
    DUSP1 Human Pre-designed siRNA Set A
  • HY-178978
    α,δ-NAG

    		Drug Derivative Phosphatase ERK Ras Inflammation/Immunology
    α,δ-NAG is an orally active glutaminase-resistant less-hydrolyzable L-Glutamine derivative. α,δ-NAG is a G protein-coupled receptor (GPCR) allosteric modulator. α,δ-NAG suppresses neutrophilic airway inflammation by activating the GPCR/ERK/MKP-1 pathway. α,δ-NAG can be used for the researches of inflammation and immunology, such as asthma [1].
    α,δ-NAG
  • HY-108543R
    NSC 95397 (Standard)

    		Reference Standards Phosphatase Apoptosis Cancer
    NSC 95397 (Standard) is the analytical standard of NSC 95397 (HY-108543). This product is intended for research and analytical applications. NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (Ki=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC50=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)) [1]. NSC 95397 inhibits mitogen-activated protein Kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway .
    NSC 95397 (Standard)
  • HY-13866R
    Ro 31-8220 mesylate (Standard)

    Ro 31-8220 methanesulfonate (Standard); Bisindolylmaleimide IX mesylate (Standard)

    		 PKC JNK Reference Standards Cardiovascular Disease Neurological Disease Cancer
    Ro 31-8220 mesylate (Standard) is the analytical standard of Ro 31-8220 mesylate (HY-13866). This product is intended for research and analytical applications. Ro 31-8220 mesylate is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 mesylate can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC [1] .
    Ro 31-8220 mesylate (Standard)
  • HY-RS23270
    Dusp1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Dusp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dusp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dusp1 Rat Pre-designed siRNA Set A
    Dusp1 Rat Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: